亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis

作者
Dantong Sun,Helei Hou,Chuantao Zhang,Xiaochun Zhang
出处
期刊:OncoTargets and Therapy [Dove Medical Press]
卷期号:Volume 11: 6539-6554 被引量:21
标识
DOI:10.2147/ott.s176429
摘要

BACKGROUND AND PURPOSE: Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that targets VEGFR-2. Recent clinical trials have revealed its broad-spectrum anticancer effect. However, most recent studies of apatinib have involved single-arm studies with insufficient cases, different doses of drugs, and different incidences of adverse events (AEs), which has resulted in a lack of accurate measurement of the efficacy and safety of apatinib. Thus, we performed this meta-analysis to evaluate the efficacy and safety of apatinib. METHODS: In total, 21 studies from five databases (PubMed, ScienceDirect, ClinicalTrials.gov, China National Knowledge Infrastructure [CNKI], and Cochrane Library) were included in this meta-analysis. All statistical analyses in this meta-analysis were performed using Stata 14.0 software. We used objective response rate (ORR) and disease control rate (DCR) to evaluate the efficacy of apatinib for five major types of solid tumors. Additionally, we used the total incidence of AEs and the incidence of the three most common grade 3-4 AEs to evaluate the safety of apatinib. RESULTS: The pooled results for the efficacy of apatinib in the treatment of different types of solid tumors revealed that patients treated with apatinib exhibited good disease control. In addition, it was likely that an increased dose of apatinib resulted in an increased ORR in lung and breast cancer and an increased DCR in liver and gastric cancer. Although AEs appeared in 84% of patients included in this meta-analysis, most of these AEs were of grades 1-2 and were well tolerated and controlled. The most common grade 3-4 AEs included hypertension, hand-foot syndrome, and proteinuria. Importantly, there were no significant differences in these grade 3-4 AEs with higher doses of apatinib. CONCLUSION: Apatinib is a novel VEGFR-2 inhibitor with proven efficacy and safety for solid tumors. The meta-analysis reveals the broad-spectrum anticancer effect of apatinib.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
锅锅锅完成签到 ,获得积分10
刚刚
AiQi完成签到 ,获得积分10
1秒前
3秒前
万能图书馆的应助被吐司采纳,获得10
8秒前
海洋球发布了新的文献求助10
9秒前
dolabmu完成签到 ,获得积分10
11秒前
魔幻雅柔完成签到,获得积分10
12秒前
月亮打烊完成签到 ,获得积分10
15秒前
文静楷瑞完成签到,获得积分10
18秒前
fx完成签到 ,获得积分10
20秒前
20秒前
fantasy的应助被十三采纳,获得10
21秒前
深情安青的应助被outlast采纳,获得10
26秒前
十三完成签到,获得积分10
27秒前
28秒前
32秒前
拼搏问薇完成签到 ,获得积分10
33秒前
34秒前
Abcqqq完成签到 ,获得积分10
34秒前
海洋球完成签到,获得积分10
36秒前
ll完成签到,获得积分20
36秒前
小蘑菇的应助被xx2026采纳,获得10
37秒前
38秒前
kxz完成签到 ,获得积分10
38秒前
39秒前
gale发布了新的文献求助10
42秒前
红墨发布了新的文献求助30
43秒前
45秒前
怕黑的驳完成签到,获得积分10
46秒前
48秒前
49秒前
50秒前
51秒前
吐司发布了新的文献求助10
52秒前
冷静新烟完成签到,获得积分10
52秒前
gale完成签到,获得积分10
55秒前
1分钟前
1分钟前
TIDUS完成签到,获得积分10
1分钟前
独特的念柏完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195004
求助须知:如何正确求助?哪些是违规求助? 9580729
关于积分的说明 21872554
捐赠科研通 7794720
什么是DOI,文献DOI怎么找? 3437836
关于科研通互助平台的介绍 2561159
邀请新用户注册赠送积分活动 2484541